On the one hand, the LT/LIGHT/HVEM (LTα3/HVEM and LIGHT/HVEM) bidirectional interaction can drive myeloid cell activation, licensing of dendritic cells for antigen presentation, NK cell activation, and T cell co-stimulation, thus promoting anti-tumor responses [4, 37, 53, 54]. The gene discussed is TNFRSF14; the disease is neoplasm.